Omega Fund Management, Llc
- Regulatory AUM
- $1.7B
- Discretionary
- $1.7B
- Clients
- 5
- Avg AUM / client
- $343M
- Accounts
- 5
- Employees
- 21
AUM over time
Reported AUM from Form ADV filings, plotted by filing date · as of Mar 26, 2026
Investments (13F portfolio — 10 positions, $163,149,231)
13F period Mar 31, 2026| # | Issuer | Class | Value | Shares | % of 13F | % of AUM |
|---|---|---|---|---|---|---|
| 1 | Bicara Therapeutics Inc. | Common Stock | $47,579,864 | 2,392,150 | 29.2% | 2.78% |
| 2 | Nuvation Bio Inc. | Common Stock Class A | $34,667,872 | 8,081,089 | 21.2% | 2.02% |
| 3 | Bridge Bio Oncology Therapeutics Inc. | Common Stock | $29,442,466 | 3,289,661 | 18.0% | 1.72% |
| 4 | Kestra Med Technologies Ltd | Common Stock | $20,371,430 | 1,022,149 | 12.5% | 1.19% |
| 5 | Beta Bionics Inc. | Common Stock | $13,188,154 | 1,316,183 | 8.08% | 0.77% |
| 6 | En Gene Holdings Inc. | Common Stock | $5,967,991 | 876,357 | 3.66% | 0.35% |
| 7 | Alumis Inc. | Common Stock | $5,314,848 | 241,255 | 3.26% | 0.31% |
| 8 | Sana Biotechnology, Inc. | Common Stock | $2,430,000 | 843,750 | 1.49% | 0.14% |
| 9 | Imagene Bio, Inc. | Common Stock | $2,276,805 | 455,361 | 1.4% | 0.13% |
| 10 | Replimune Group | Common Stock | $1,909,801 | 248,672 | 1.17% | 0.11% |
Top 25 of 10 positions from the manager's latest Form 13F · source filing (EDGAR) ↗. 13F covers long US-listed positions only. "% of AUM" is share of the firm's total regulatory AUM (Form ADV Item 5.F).
Who they serve
| Client type | Clients | AUM | % of AUM |
|---|---|---|---|
| Pooled investment vehicles (non-investment companies) | 5 | $1.7B | 100.0% |
Private funds (8)
Reported in Form ADV Section 7.B.(1), filing of Mar 2024 · $694M combined gross assets
| Fund | Type | Domicile | Gross assets | Owners |
|---|---|---|---|---|
| Omega Fund Vii, L.P. | Private Equity Fund | Cayman Islands | $324M | 87 |
| Omega Fund Vi, L.P. | Private Equity Fund | Cayman Islands | $268M | 45 |
| Omega Fund V, L.P. | Private Equity Fund | Cayman Islands | $67.8M | 34 |
| Omega Fund Iv, L.P. | Private Equity Fund | Cayman Islands | $28.6M | 37 |
| Net Assets Of Omega Fund Iii, L.P. | Private Equity Fund | Cayman Islands | $3.1M | 15 |
| Omega Fund Ii, Lp | Private Equity Fund | Cayman Islands | $1.7M | 6 |
| Life Sciences Holdings Spv I Fund, Lp | Private Equity Fund | Cayman Islands | $190K | 1 |
| Omega Fund Viii, L.P. | Private Equity Fund | Cayman Islands | $0 | 42 |
People (5)
| Name | Role / title | Credentials | With firm since | Ownership |
|---|---|---|---|---|
| Stampacchia, Otello, (Nmn) | Manager | Feb 2015 (12y) | ≈ 56.25% – 100% via Clessidra, Llc | |
| Russell, Mark, Emerson | Chief Compliance Officer | Mar 2016 (10y) | Less than 5% | |
| Nessi, Claudio, Pier Antonio | Manager & Member | Nov 2016 (10y) | 10% – 25% | |
| Pearsall, Alexandra, Rankel | Chief Financial Officer | Jul 2020 (6y) | Less than 5% | |
| Draetta, Francesco, Luigi | Manager & Member | Oct 2023 (3y) | 10% – 25% |
Entity owners (Schedule A/B)
| Entity | Title / status | Since | Sch. | Ownership |
|---|---|---|---|---|
| Clessidra, Llc | Member | Apr 2015 | A | 75% or more |
Undisclosed: 0% – 5% of the firm is not attributable from the filed Schedule A bands.
Estimated effective ownership (look-through of filed bands):
- Stampacchia, Otello, (Nmn): 75% – 100% of Clessidra, Llc × 75% – 100% direct ≈ 56.25% – 100% of the firm
Roster from the IAPD representatives feed; ownership and acquisition dates from Form ADV Schedule A/B. "Since" is the earliest filed registration or acquisition date.
Private funds (8, $694M gross assets)
| Fund | Type | Gross assets | Min. investment | Owners |
|---|---|---|---|---|
| Omega Fund Vii, L.P. | Private Equity Fund | $324M | $5.0M | 87 |
| Omega Fund Vi, L.P. | Private Equity Fund | $268M | $5.0M | 45 |
| Omega Fund V, L.P. | Private Equity Fund | $67.8M | $1.0M | 34 |
| Omega Fund Iv, L.P. | Private Equity Fund | $28.6M | $1.0M | 37 |
| Net Assets Of Omega Fund Iii, L.P. | Private Equity Fund | $3.1M | $1.0M | 15 |
| Omega Fund Ii, Lp | Private Equity Fund | $1.7M | $1.4M | 6 |
| Life Sciences Holdings Spv I Fund, Lp | Private Equity Fund | $190K | $1.0M | 1 |
| Omega Fund Viii, L.P. | Private Equity Fund | $0 | $1.0M | 42 |
From Form ADV Section 7.B private fund reporting.
Documents (1 archived)
| Form | Period | Size | |
|---|---|---|---|
| Form ADV (full filing) | 03/26/2026 | 2.43 MB | View · PDF · Source ↗ |
Archived copies of the firm's regulatory filings, versioned by content hash.
Disciplinary disclosures
No disciplinary events reported on the firm's latest Form ADV filing.
How they charge
- • Percentage of assets under management
- • Other fees
- • CARRIED INTEREST
Services
- • Portfolio management for pooled investment vehicles
Custody
Firm reports having custody of client funds or securities (Item 9.A).
No custodian data reported or mined yet.
Source
All data on this page comes from this firm's Form ADV filings, reproduced without modification. Latest filing: Mar 26, 2026.
View current Form ADV (SEC/IAPD) ↗